**Appendix Table 1.** Univariate and multivariate analysis of chronic oedema.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Univariate** | **Multivariate** |
| **Parameter** | **n** | **OR (95% CI)** | **p\*** | **OR (95% CI)** | **p\*** |
| **Hypofractionation**NoYes | 446340 | 10.20 (0.09-0.44) | **0.0001** | 10.18 (0.04-0.75) | **0.018** |
| **EIC**AbsentPresent  |  548 169 | 13.0 (1.66-5.46) | **0.0001** | 11.06 (0.54-2.12) | 0.86 |
| **Boost dose**None <10 Gy or equivalent≥10 Gy or equivalent | 51506229 | 11.42 (0.18-11.05)9.02 (1.21-67.45) | 0.74**0.032** | 10.98 (0.12-8.11)3.37 (0.40-28.38) | 0.980.26 |
| **Breast size (cc)**≤492 (median)>492 | 365364 | 12.67 (1.41-5.05) | **0.003** | 11.70 (0.80-3.58) | 0.17 |
| **Dmax/Prescribed dose** >107% ≤107% | 273455 | 10.31 (0.14-‘-66) | **0.003** | 11.84 (0.53-6.37) | 0.34 |

**Appendix Table 2.** Univariate and multivariate analysis of acute erythema/hyperpigmentation.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Univariate** | **Multivariate** |
| **Parameter** | **N** | **OR (95% CI)** | **p\*** | **OR (95% CI)** | **p\*** |
| **HER2 status**NegativePositiveEquivocal | 58510123 | 10.30 (0.14-0.63)0.16 (0.02-1.18) | **0.002**0.072 | 10.16 (0.04-0.75)0.14 (0.02-1.10) | **0.02**0.062 |
| **Trastuzumab** No  Yes  | 71571 | 10.39 (0.18-0.87) | **0.022** | 11.38 (0.26-7.36) | 0.70 |
| **Smoking habits**NoYes | 594114 | 12.14 (1.37-3.32) | **0.001** | 11.83 (1.06-3.15) | **0.03** |
| **Boost dose**None <10 Gy or equivalent≥10 Gy or equivalent | 51506229 | 11.80 (0.75-4.34)2.60 (1.06-6.41) | 0.19**0.038** | 12.11 (0.61-7.37)1.48 (0.38 (5.73) | 0.240.57 |
| **Breast size (cc)**≤492 (median)>492 | 365364 | 11.78 (1.24-2.54) | **0.002** | 11.97 (1.26-3.07) | **0.003** |

**Appendix Table 3.** Univariate and multivariate analysis of chronic erythema/hyperpigmentation.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Univariate** | **Multivariate** |
| **Parameter** | **n** | **OR (95% CI)** | **p\*** | **OR (95% CI)** | **p\*** |
| **Hypofractionation**NoYes | 446340 | 10.40 (0.25-0.63) | **0.0001** | 10.76 (0.34-1.67) | 0.49 |
| **EIC**AbsentPresent  | 548169 | 12.39 (1.54-3.71) | **0.0001** | 11.65 (0.98-2.79) | 0.061 |
| **Final surgical margins**≥2 mm0.1-1.9 mmPositive (not re-excised) | 6757529 | 11.13 (0.58-2.23)3.47 (1.56-7.71) | 0.72**0.002** | 11.02 (0.48-2.17)2.23 (0.92-5.40) | 0.970.076 |
| **Boost dose**None <10 Gy or equivalent≥10 Gy or equivalent | 51506229 | 16.10 (0.83-45.02)15.43 (2.08-114.3) | 0.076**0.007** | 15.14 (0.68-38.66)7.15 (0.91-55.93) | 0.110.061 |
| **Breast size (cc)**≤492 (median)>492 | 365364 | 11.58 (1.04-2.41) | **0.034** | 11.42 (0.87-2.32) | 0.17 |
| **Dmax/Prescribed dose** >107% ≤107% | 273455 | 10.45 (0.28-0.73) | **0.001** | 10.79 (0.37-1.69) | 0.54 |

**Appendix Table 4.** Univariate and multivariate analysis of acute wet desquamation.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Univariate** | **Multivariate** |
| **Parameter** | **n** | **OR (95% CI)** | **p\*** | **OR (95% CI)** | **p\*** |
| **Hypofractionation** No Yes | 446340 | 10.14 (0.03-0.61) | **0.009** | 10.07 (0.009-0.59) | **0.014** |
| **Dmax/Prescribed dose** >107% ≤107% | 273455 | 10.29 (0.08-0.99) | **0.047** | 12.11 (0.36-12.48) | 0.41 |

\* In bold reported p-value <0.05.